Edgewise Therapeutics
Jonathan Lane has been making significant contributions to the field of chemistry and pharmaceuticals for over two decades. With a Ph.D. in Organic Chemistry, Jonathan has held various roles ranging from Research Scientist to Senior Director in companies like Edgewise Therapeutics, Esperion, and Mile High Labs. Jonathan's expertise in Chemistry Manufacturing and Controls has been instrumental in their career progression, showcasing their dedication to advancing drug development processes. Prior to their industry experience, Jonathan also served as a Postdoctoral Fellow at Colorado State University.
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.